Background
Approximately 170 million people globally are infected by hepatitis C virus (HCV). In 2013, 17 000 patients were estimated to be HCV infected in Denmark. Only half of them have been diagnosed (1) . HCV may cause liver cirrhosis and other liver-related complication such as hepatocellular carcinoma (HCC), which is the leading cause of liver transplants in the United States. (2, 3, 4, 5) Of the six HCV genotypes, genotype 1 is the most common, but also the most difficult to eradicate by therapy (8, 9) . In 2011, boceprevir (BOC), one of the first protease inhibitors, was approved for treatment of HCV genotype 1 infection in previously untreated and treated patients.
Objectives
The aim of this study was to evaluate the cost-effectiveness of boceprevir therapy in combination with pegylated interferon plus ribavirin (PEG+R), compared to PEG+R therapy alone, genotype 1 HCV patients, including treatment naïve as well as treatment experienced patients.
Methods
A Markov model simulating antiviral therapy and disease progression was developed to estimate lifetime healthcare costs and clinical outcomes of alternative treatment strategies. The model simulated the treatment regimens of dual therapy (PEG+R) and triple therapy (PEG+R+BOC), respectively, as recommended in the summary of product characteristics (SPC) and the Danish treatment guidelines. Data on clinical efficacy was taken from phase III clinical trials (SPRINT-2 and RESPOND-2). The model projected the expected lifetime healthcare costs and clinical outcomes in quality-adjusted life years (QALY). Costs were measured in 2012 Danish kroner (DKK) and clinical outcomes in (QALYs). Both costs and QALYs were discounted at 3 % per year. Incremental cost-effectiveness ratio (ICER) was estimated for treatment naïve and experienced patients in comparison with PEG+R-based therapy. Deterministic and probabilistic sensitivity analyses (PSA) on clinical inputs, costs, health state utility values, and sustained virologic response (SVR) rates were performed to assess the overall decision uncertainty. 
Model inputs
All patient characteristics were based on information for the Danish database InfCare hepatitis database. (table 1) . Treatment related parameters were estimated from SPRINT-2 and RESPOND-2. Information of the probability of receiving liver transplant was estimated from the Nordic liver transplant register (table 2). All health states and treatment related quality of life weights were obtained from previously published studies (table 3) . Health state costs were based on previously published studies as well as DRG-tarifs (table 4). (14) 0.76 (0.68-0.83) F2 (14) 0.76 (0.68-0.83) F3 (14) 0 (17) 13 600 Decompensated cirrhosis (first year) (17) 47 050 Decompensated cirrhosis (subsequent years) (17) 47 050 Hepatocellular carcinoma (first year) (17) 62 040 Hepatocellular carcinoma (subsequent years) (17) 2 850 Liver transplant (first year) (17) 865 253 Liver transplant (subsequent years) (17) 61 306 Discount Rate for future costs (17) 3% Time Horizon Lifetime
Results
The ICER for PEG+R+BOC therapy versus standard therapy with PEG+R was DKK 241,774 for treatment naïve HCV patients and DKK 98,371 for treatment experienced patients. PSA for treatment naïve patients showed a probability of cost-effectiveness of PEG+R+BOC therapy compared to PEG+R of more than 65 % at a willingness-to-pay threshold of DKK 300,000 (approx. £30,000). 
